Glaucoma Clinical Trial
Official title:
Neurovascular Coupling in Eyes of Glaucoma Patients
We hypothesize that glaucoma patients demonstrate an impaired retinal vascular response to
the flicker stimulus, and that this disturbance is predictive of the progression of
glaucomatous damage.
The response of a major temporal superior and inferior retinal artery and vein to a 60
seconds 12.5 Hz flicker light stimulation in 50 glaucoma patients, 50 ocular hypertensives
and 50 controls (using the Retinal Vessel Analyzer) and to investigate how intraocular
pressure relates to neurovascular coupling. In addition, 50 glaucoma patients and 50 ocular
hypertension patients will be followed for 3 years for functional (visual field, automated
perimetry with Octopus device) and morphological (retinal nerve fiber layer thickness,
Optical Coherence Tomography Stratus ocular coherence tomography (OCT) device) glaucomatous
damage progression, in order to test the predictive power of the retinal vascular flicker
response for glaucoma progression.
Rationale: The term neurovascular coupling refers to the vascular response to an increased
neuronal activity. The contact of the nerve terminals to the cortical blood vessels is
mostly realized through astrocytes. A major defining property of glaucoma, cupping of the
optic disc, implies tissue remodeling of the optic nerve head and involves an astrocytic
responses. A malfunction of the astrocytes in glaucoma may lead not only to the hallmark of
glaucoma, cupping and death of retinal ganglion cells, but also to an accompanying or even
preceding disturbance in ocular neurovascular coupling. The retinal vascular bed was chosen
because of the high reproducibility of the dynamic retinal vessel diameter analysis and
because recently the hypoxia-inducible factor 1α was found not only in the glia of the optic
nerve head but also in the retina of glaucomatous donor eyes and predominantly in retinal
locations closely concordant with the locations of visual field defects recorded in these
eyes, raising questions about the site of primary damage in glaucoma. It is hoped that this
research project will help provide a workable tool and a model able not only to identify a
risk factor for glaucoma, but in the future to explore possible therapeutic avenues to
modify the course of the disease.
Working hypothesis: We hypothesize that glaucoma patients demonstrate an impaired retinal
vascular response to the flicker stimulus, and that this disturbance is predictive of the
progression of glaucomatous damage
Subjects and Methods The present protocol intends to explore the response of a major
temporal superior and inferior retinal artery and vein to a 60 seconds 12.5 Hz flicker light
stimulation in 50 glaucoma patients, 50 ocular hypertensives and 50 controls (using the
Retinal Vessel Analyzer) and to investigate how intraocular pressure relates to
neurovascular coupling. In addition, 50 glaucoma patients and 50 ocular hypertension
patients will be followed for 3 years for functional (visual field, automated perimetry with
Octopus device) and morphological (retinal nerve fiber layer thickness, Optical Coherence
Tomography Stratus OCT device) glaucomatous damage progression, in order to test the
predictive power of the retinal vascular flicker response for glaucoma progression. Patients
will be recruited in the University Eye Clinic Basel, a notification in the University
Hospital of Basel and/or advertisement in a newspaper will inform potential healthy
volunteers of the opportunity to participate in a scientific research project.
Study Course: Study is divided in the cross-sectional and in the cohort part. In the former,
first the screening examination will be performed, to establish an eligibility of a patient
/ control subject for the study. Thereafter, the measurements described above will follow,
which will conclude the cross-sectional part of the study. Glaucoma patients and patients
with ocular hypertension will be offered a possibility to enter the cohort-study, with a
3-year follow-up embedded in the clinical routine and consisting of biannual repeated
measurements outlined above.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A |